6841094
Last Update Posted: 2025-02-24
Recruiting has ended
All Genders accepted | 18 Years + |
54 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
Eligibility
Relevant conditions:
IgA Nephropathy
Immunoglobulin A Nephropathy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov